Lipomedix most advanced program is Promitil® (LPMX-1), which has completed a clinical Phase 1a study in cancer patients, and is currently tested in colon cancer patients in a Phase 1b trial. Promitil is also being investigated in combination with Radiotherapy as a radiosensitizer in preclinical studies.


Further to this, Lipomedix pipeline includes two other products currently under preclinical development.

  • Targeted form of Promitil® (LPMX-2) directed to folate receptors of cancer cells, for intra-vesical delivery in the treatment of superficial bladder cancer.
  • A new and proprietary multidrug liposome formulation with greatly enhanced anticancer activity.